These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 21428831)

  • 1. Are meaningful predictions of toxicological outcomes in clinical trials based on in vitro diagnostics of preclinical drug candidates possible?
    Kroll F; Dreger M
    Future Med Chem; 2010 Nov; 2(11):1613-7. PubMed ID: 21428831
    [No Abstract]   [Full Text] [Related]  

  • 2. Metabolomics in toxicology: preclinical and clinical applications.
    Robertson DG; Watkins PB; Reily MD
    Toxicol Sci; 2011 Mar; 120 Suppl 1():S146-70. PubMed ID: 21127352
    [No Abstract]   [Full Text] [Related]  

  • 3. Mass spectrometry-based proteomics in preclinical drug discovery.
    Schirle M; Bantscheff M; Kuster B
    Chem Biol; 2012 Jan; 19(1):72-84. PubMed ID: 22284356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strategies at the interface of drug discovery and development: early optimization of the solid state phase and preclinical toxicology formulation for potential drug candidates.
    Palucki M; Higgins JD; Kwong E; Templeton AC
    J Med Chem; 2010 Aug; 53(16):5897-905. PubMed ID: 20527889
    [No Abstract]   [Full Text] [Related]  

  • 5. Metabolomics and its potential in drug development.
    Beyoğlu D; Idle JR
    Biochem Pharmacol; 2013 Jan; 85(1):12-20. PubMed ID: 22935449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent advances in physicochemical and ADMET profiling in drug discovery.
    Wang J; Skolnik S
    Chem Biodivers; 2009 Nov; 6(11):1887-99. PubMed ID: 19937823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic profiling as a tool for understanding mechanisms of toxicity.
    Clarke CJ; Haselden JN
    Toxicol Pathol; 2008 Jan; 36(1):140-7. PubMed ID: 18337232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genomics and systems biology--how relevant are the developments to veterinary pharmacology, toxicology and therapeutics?
    Witkamp RF
    J Vet Pharmacol Ther; 2005 Jun; 28(3):235-45. PubMed ID: 15953196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative proteomics for drug toxicity.
    Gao Y; Holland RD; Yu LR
    Brief Funct Genomic Proteomic; 2009 Mar; 8(2):158-66. PubMed ID: 19351682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro testing of drug absorption for drug 'developability' assessment: forming an interface between in vitro preclinical data and clinical outcome.
    Sun D; Yu LX; Hussain MA; Wall DA; Smith RL; Amidon GL
    Curr Opin Drug Discov Devel; 2004 Jan; 7(1):75-85. PubMed ID: 14982151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Physiochemical drug properties associated with in vivo toxicological outcomes.
    Hughes JD; Blagg J; Price DA; Bailey S; Decrescenzo GA; Devraj RV; Ellsworth E; Fobian YM; Gibbs ME; Gilles RW; Greene N; Huang E; Krieger-Burke T; Loesel J; Wager T; Whiteley L; Zhang Y
    Bioorg Med Chem Lett; 2008 Sep; 18(17):4872-5. PubMed ID: 18691886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An FDA perspective on the nonclinical use of the X-Omics technologies and the safety of new drugs.
    Jacobs A
    Toxicol Lett; 2009 Apr; 186(1):32-5. PubMed ID: 18809476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel biomarkers of acute kidney toxicity.
    Goodsaid FM; Blank M; Dieterle F; Harlow P; Hausner E; Sistare F; Thompson A; Vonderscher J
    Clin Pharmacol Ther; 2009 Nov; 86(5):490-6. PubMed ID: 19710639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabonomic modeling of drug toxicity.
    Keun HC
    Pharmacol Ther; 2006 Jan; 109(1-2):92-106. PubMed ID: 16051371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The safety of drugs].
    de Cea Lavech de Chancy H
    Rev Clin Esp; 1990 Sep; 187(4):184-90. PubMed ID: 2091076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive toxicogenomics in preclinical discovery.
    Barros SA; Martin RB
    Methods Mol Biol; 2008; 460():89-112. PubMed ID: 18449484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Strategies for dealing with metabolite elucidation in drug discovery and development.
    Nassar AE; Talaat RE
    Drug Discov Today; 2004 Apr; 9(7):317-27. PubMed ID: 15037231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel genomic methods for drug discovery and mechanism-based toxicological assessment.
    Gant TW; Zhang SD; Taylor EL
    Curr Opin Drug Discov Devel; 2009 Jan; 12(1):72-80. PubMed ID: 19152215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical predictors of clinical safety: opportunities for improvement.
    Sistare FD; DeGeorge JJ
    Clin Pharmacol Ther; 2007 Aug; 82(2):210-4. PubMed ID: 17507920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pharmacokinetic and metabolic studies in the development of drugs].
    Vereczkey L
    Acta Pharm Hung; 1995 Jul; 65(4):105-11. PubMed ID: 7572191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.